Browse result page of B3Pdb
The total number entries retrieved from this search are 76, scroll left/right for detailed information.
| B3pdbIDb3pdb_0008 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA N315 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONAlone | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT6.3 ± 1.3 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0009 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONN-terminal Fmoc group was removed and the propiola | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA N315 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONAlone | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT1.6 ± 0.9micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0010 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONN-terminal Fmoc group was removed and the propiola | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA N315 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONAlone | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT1.6 ± 0.8 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0011 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA N315 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows the resistance | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONAlone | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT12.5 ± 3.2 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0012 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA N315 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONAlone | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT6.3 ± 1.6 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0013 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATION6-carboxyfluorescein (Fl) was coupled to the N-ter | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA N315 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONAlone | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT6.3 ± 1.6 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0014 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA 12673 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT6.3 ± 1.6 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0015 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONN-terminal Fmoc group was removed and the propiola | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA 12673 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT1.6 ± 0.9 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0016 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONN-terminal Fmoc group was removed and the propiola | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA 12673 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT1.6 ± 0.7 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0017 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA 12673 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows high sensitivity | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT0.8 ± 0.4 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0018 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA 12673 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows high sensitivity | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT0.8 ± 0.3 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0019 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATION6-carboxyfluorescein (Fl) was coupled to the N-ter | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA 12673 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows high sensitivity | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT0.8 ± 0.3 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0020 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA hetero-VISA 6347b | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows high sensitivity | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT12.5 ± 3.2 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0021 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONN-terminal Fmoc group was removed and the propiola | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA hetero-VISA 6347b | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT1.6 ± 0.3 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0022 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONN-terminal Fmoc group was removed and the propiola | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA hetero-VISA 6347b | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT3.1 ± 0.8 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0023 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA hetero-VISA 6347b | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT1.6 ± 0.4 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0024 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA hetero-VISA 6347b | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT3.1 ± 0.8 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0025 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATION6-carboxyfluorescein (Fl) was coupled to the N-ter | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA hetero-VISA 6347b | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT3.1 ± 0.8 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0026 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecium 3934825 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT12.5 ± 3.4 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0027 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONN-terminal Fmoc group was removed and the propiola | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecium 3934825 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows the resistance | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT50.0 ± 10.2 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0028 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONN-terminal Fmoc group was removed and the propiola | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecium 3934825 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows the resistance | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT25.0 ± 5.1 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0029 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecium 3934825 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT12.5 ± 3.2 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0030 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecium 3934825 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT6.3 ± 1.7 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0031 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATION6-carboxyfluorescein (Fl) was coupled to the N-ter | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecium 3934825 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT6.3 ± 1.7 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0032 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecalis 3937158 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT12.5 ± 2.2 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0033 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONN-terminal Fmoc group was removed and the propiola | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecalis 3937158 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT6.3 ± 1.6 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0034 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONN-terminal Fmoc group was removed and the propiola | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecalis 3937158 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows the resistance | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT25.0 ± 6.5 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0035 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecalis 3937158 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows the resistance | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT25.0 ± 5.1 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0036 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecalis 3937158 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows the resistance | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT25.0 ± 6.9 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0037 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATION6-carboxyfluorescein (Fl) was coupled to the N-ter | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecalis 3937158 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows the resistance | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT25.0 ± 6.9 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0042 | PEPTIDE NAMEMVIIA (ziconotide) | PEPTIDE SEQUENCE (1-letter)CKGKGAKCSRLMYDCCTGSCRSGKC | PEPTIDE SEQUENCE (3-letter)CysLysGlyLysGlyAlaLysCysSerArgLeuMetTyrAspCysCysThrGlySerCysArgSerGlyLysCys | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION TAT-transducing domain was fused at C-terminal | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH25 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDENA | SMILESN[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCSC)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)NCC(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CO)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)O | CELL LINEHEK293 cells | In vitro CONCENTRATIONNA | In vitro METHODAcetic Acid-Induced WRITHING test | In vitro RESULTInhibitory activity toward N-type calcium channels. | ANIMAL MODELKunming mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntranasal and Intervenous | In vivo METHODTremor Symptom Test | In vivo RESULTIt induces tremor symptoms | ACTIONIt showed that C-terminal fusion with TAT peptide render its BBB penetration capacity, without signi | TRANSPORT TYPEReceptor-mediated transcytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONComined with TAT-protein | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT0.0436 micromolar | LABELNA | PMID 31083641 |
| B3pdbIDb3pdb_0049 | PEPTIDE NAMEgH625Cys | PEPTIDE SEQUENCE (1-letter)HGLASTLTRWAHYNALIRAF | PEPTIDE SEQUENCE (3-letter)HisGlyLeuAlaSerThrLeuThrArgTrpAlaHisTyrAsnAlaLeuIleArgAlaPhe | N-TERMINAL MODIFICATIONAcetylaed at N-terminal | C-TERMINAL MODIFICATION Cys-CONH2 group is attached at C-terminal | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(CC1=CN=C-N1)C(=O)NCC(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(=CN2)C1=C2C=CC=C1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)O | CELL LINEBMECs | In vitro CONCENTRATION5 micromolar | In vitro METHODFluorescence microscopy | In vitro RESULTLiposomes preparations were non-toxic for the endothelial cells and improves the transfer of liposom | ANIMAL MODELMouse | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy | In vivo RESULTgH625 ameliorates the efficiency of liposomes to deliver. PACAP | ACTIONgH625-liposomes represent a promising strategy to deliver therapeutic agents to CNS and to provide a | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONComined with liposome | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 31235716 |
| B3pdbIDb3pdb_0162 | PEPTIDE NAMEASA-ApoEI | PEPTIDE SEQUENCE (1-letter)TEELRVRLASHLRKLRKRLLRDA | PEPTIDE SEQUENCE (3-letter)ThrGluGluLeuArgValArgLeuAlaSerHisLeuArgLysLeuArgLysArgLeuLeuArgAspAla | N-TERMINAL MODIFICATIONConjugated with ASA drug | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH23 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINECHO cell line | In vitro CONCENTRATION2.5 microgram/ ml | In vitro METHODcellular uptake assay | In vitro RESULT93 % cellular uptake | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONLysosomal disorder | RESPONSENA | RESULTNA | LABELNA | PMID 24573272 |
| B3pdbIDb3pdb_0167 | PEPTIDE NAMEASA-ApoEI | PEPTIDE SEQUENCE (1-letter)TEELRVRLASHLRKLRKRLLRDA | PEPTIDE SEQUENCE (3-letter)ThrGluGluLeuArgValArgLeuAlaSerHisLeuArgLysLeuArgLysArgLeuLeuArgAspAla | N-TERMINAL MODIFICATIONConjugated with ASA drug | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH23 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINEbEND cell line | In vitro CONCENTRATION2.5 microgram/ ml | In vitro METHODcellular uptake assay | In vitro RESULT21.2 % cellular uptake | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONLysosomal disorder | RESPONSENA | RESULTNA | LABELNA | PMID 24573272 |
| B3pdbIDb3pdb_0172 | PEPTIDE NAMEASA-ApoEI | PEPTIDE SEQUENCE (1-letter)TEELRVRLASHLRKLRKRLLRDA | PEPTIDE SEQUENCE (3-letter)ThrGluGluLeuArgValArgLeuAlaSerHisLeuArgLysLeuArgLysArgLeuLeuArgAspAla | N-TERMINAL MODIFICATIONConjugated with ASA drug | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH23 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINEPBCECs cell line | In vitro CONCENTRATION0.02% cells were added | In vitro METHODBasolateral screening assay | In vitro RESULT200% transfer | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEBasolateral | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONLysosomal disorder | RESPONSENA | RESULTNA | LABELNA | PMID 24573272 |
| B3pdbIDb3pdb_0193 | PEPTIDE NAMEgH625 | PEPTIDE SEQUENCE (1-letter)HGLASTLTRWAHYNALIRAFGGG | PEPTIDE SEQUENCE (3-letter)HisGlyLeuAlaSerThrLeuThrArgTrpAlaHisTyrAsnAlaLeuIleArgAlaPheGlyGlyGly | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONChemically synthesized | PEPTIDE LENGTH23 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINEHuman neuroblastoma cell line SH-SY5Y | In vitro CONCENTRATION5*10^4 cells/well | In vitro METHODSpectorcluorometric analysis | In vitro RESULT20% fluoroscence measured at 1 micromolar peptide concentration | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPETranscytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 25792823 |
| B3pdbIDb3pdb_0194 | PEPTIDE NAMEgH625 | PEPTIDE SEQUENCE (1-letter)HGLASTLTRWAHYNALIRAFGGG | PEPTIDE SEQUENCE (3-letter)HisGlyLeuAlaSerThrLeuThrArgTrpAlaHisTyrAsnAlaLeuIleArgAlaPheGlyGlyGly | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONChemically synthesized | PEPTIDE LENGTH23 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINEHuman glioblastoma cell line U-87 | In vitro CONCENTRATION5*10^4 cells/well | In vitro METHODSpectorcluorometric analysis | In vitro RESULT35% fluoroscence measured at 1 micromolar peptide concentration | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPETranscytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 25792823 |
| B3pdbIDb3pdb_0195 | PEPTIDE NAMEgH625 | PEPTIDE SEQUENCE (1-letter)HGLASTLTRWAHYNALIRAFGGG | PEPTIDE SEQUENCE (3-letter)HisGlyLeuAlaSerThrLeuThrArgTrpAlaHisTyrAsnAlaLeuIleArgAlaPheGlyGlyGly | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONChemically synthesized | PEPTIDE LENGTH23 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINEHuman neuroblastoma cell line SH-SY5Y | In vitro CONCENTRATION5*10^4 cells/well | In vitro METHODSpectorcluorometric analysis | In vitro RESULT80% fluoroscence measured at 1 micromolar peptide concentration | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPETranscytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 25792823 |
| B3pdbIDb3pdb_0196 | PEPTIDE NAMEgH625 | PEPTIDE SEQUENCE (1-letter)HGLASTLTRWAHYNALIRAFGGG | PEPTIDE SEQUENCE (3-letter)HisGlyLeuAlaSerThrLeuThrArgTrpAlaHisTyrAsnAlaLeuIleArgAlaPheGlyGlyGly | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONChemically synthesized | PEPTIDE LENGTH23 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINEHuman glioblastoma cell line U-87 | In vitro CONCENTRATION5*10^4 cells/well | In vitro METHODSpectorcluorometric analysis | In vitro RESULT90% fluoroscence measured at 1 micromolar peptide concentration | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPETranscytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 25792823 |
| B3pdbIDb3pdb_0378 | PEPTIDE NAMEpenetratin-scFv | PEPTIDE SEQUENCE (1-letter)NSRQIKIWFQNRRMKWKKGSS | PEPTIDE SEQUENCE (3-letter)AsnSerArgGlnIleLysIleTrpPheGlnAsnArgArgMetLysTrpLysLysGlySerSer | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 23941991 |
| B3pdbIDb3pdb_0716 | PEPTIDE NAMEhuman Obestatin | PEPTIDE SEQUENCE (1-letter)FNAPFDVGIKLSGVQYQQHSQAL-NH2 | PEPTIDE SEQUENCE (3-letter)Phe-Asn-Ala-Pro-Phe-Asp-Val-Gly-Ile-Lys-Leu-Ser-Gly-Val-Gln-Tyr-Gln-Gln-His-Ser-Gln-Ala-Leu-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH23 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID NA |
| B3pdbIDb3pdb_0718 | PEPTIDE NAMEEndothelin-1 | PEPTIDE SEQUENCE (1-letter)CSCSSLMDKECVYFCHLDIIW | PEPTIDE SEQUENCE (3-letter)Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys1-Cys15, Cys3-Cys11 | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEhuman | SMILESCC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC= C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC= N3)NC(=O)[C@@H]4CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H]5CSSC[C@@H](C(=O)N[C@ H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CC6=CC=CC=C6)CC7=CC=C(C=C7)O)C(C)C)NC (=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@ @H](NC(=O)[C@@H](NC5=O)CO)CO)CC(C)C)CCSC)CC(=O)O)CCCCN)CCC(=O)O)CO)N | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID NA |
| B3pdbIDb3pdb_0775 | PEPTIDE NAMEmouse Obestatin | PEPTIDE SEQUENCE (1-letter)FNAPFDVGIKLSGAQYQQHGRAL-NH2 | PEPTIDE SEQUENCE (3-letter)Phe-Asn-Ala-Pro-Phe-Asp-Val-Gly-Ile-Lys-Leu-Ser-Gly-Ala-Gln-Tyr-Gln-Gln-His-Gly-Arg- Ala-Leu-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH23 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEnon saturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional influx rate constant | RESULT0.00186 mL/(g x min) | LABELDirect iodination | PMID 16476508 |
| B3pdbIDb3pdb_0776 | PEPTIDE NAMEmouse Obestatin | PEPTIDE SEQUENCE (1-letter)FNAPFDVGIKLSGAQYQQHGRAL-NH2 | PEPTIDE SEQUENCE (3-letter)Phe-Asn-Ala-Pro-Phe-Asp-Val-Gly-Ile-Lys-Leu-Ser-Gly-Ala-Gln-Tyr-Gln-Gln-His-Gly-Arg- Ala-Leu-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH23 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEnon saturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEInitial disrobution volume | RESULT0.01853 ml/g | LABELDirect iodination | PMID 16476508 |
| B3pdbIDb3pdb_0985 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL-NH2 | PEPTIDE SEQUENCE (3-letter)Ala-Gly-Tyr-Leu-Leu-Gly-Lys-Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEsynthetic,viral | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODEfflux study ICU | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEBrain elemination rate constant | RESULT0.0866 min-1 | LABELDirect iodination | PMID 26465925 |
| B3pdbIDb3pdb_0986 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL-NH2 | PEPTIDE SEQUENCE (3-letter)Ala-Gly-Tyr-Leu-Leu-Gly-Lys-Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEsynthetic,viral | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODCapillary depletion | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSE% capillary | RESULT14.96% | LABELDirect iodination | PMID 26465925 |
| B3pdbIDb3pdb_0987 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL-NH2 | PEPTIDE SEQUENCE (3-letter)Ala-Gly-Tyr-Leu-Leu-Gly-Lys-Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEsynthetic,viral | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODCapillary depletion | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSE% parenchyma | RESULT85.04% | LABELDirect iodination | PMID 26465925 |
| B3pdbIDb3pdb_0988 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL-NH2 | PEPTIDE SEQUENCE (3-letter)Ala-Gly-Tyr-Leu-Leu-Gly-Lys-Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEsynthetic,viral | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional influx rate constant | RESULT0.00005 mL/(g x min) | LABELDirect iodination | PMID 26465925 |
| B3pdbIDb3pdb_0989 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL-NH2 | PEPTIDE SEQUENCE (3-letter)Ala-Gly-Tyr-Leu-Leu-Gly-Lys-Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEsynthetic,viral | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEInitial disrobution volume | RESULT0.00988 ml/g | LABELDirect iodination | PMID 26465925 |
| B3pdbIDb3pdb_0990 | PEPTIDE NAMETP10-2 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKPLAALAKKIL-NH2 | PEPTIDE SEQUENCE (3-letter)Ala-Gly-Tyr-Leu-Leu-Gly-Lys-Ile-Asn-Leu-Lys-Pro-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODEfflux study ICU | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEBrain elemination rate constant | RESULT0.0624 min-1 | LABELDirect iodination | PMID 26465925 |